If You Invested in Mirion Technologies Inc (MIR)

Mirion Technologies, Inc. (NYSE: MIR) is a global provider of radiation detection, measurement, analysis, and monitoring solutions serving nuclear, medical, defense, and research end markets. The company describes its mission as empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of applications. Mirion is headquartered in Atlanta, Georgia, and operates in multiple countries.

Mirion manages its operations through groups focused on nuclear and safety and on medical applications. According to company disclosures, the Mirion Nuclear & Safety group provides proven radiation safety technologies that operate with precision for essential work within research and development laboratories, critical nuclear facilities, and front-line environments. The Mirion Medical group offers solutions that help enhance the delivery and ensure the safety of healthcare, with a focus on nuclear medicine, radiation therapy quality assurance, occupational dosimetry, and diagnostic imaging.

Business focus and end markets

Mirion states that it provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit health, safety, vitality, and technological progress. Its activities span:

• Nuclear power and safety: Radiation safety technologies and related solutions used in nuclear energy and other critical radiation environments.
• Medical applications: Solutions that support cancer care quality and safety and other medical uses of radiation.
• Defense and security: Radiation-related technologies used on the front lines and in defense contexts, as described in company materials.
• Research and laboratories: Technologies used in R&D labs and research settings where ionizing radiation is present.

Mirion’s disclosures emphasize radiation safety, science, and medicine as core themes. The company highlights its role in powering advancements in nuclear energy through radiation safety technologies and expertise, and in driving better patient outcomes in healthcare by enhancing the quality and safety of radiation-based procedures.

Organizational structure and segments

Available information indicates that Mirion’s activities are organized around two primary areas:

• Mirion Nuclear & Safety group: Focused on nuclear energy and radiation safety technologies. Company descriptions note that this group supports essential work in R&D laboratories, critical nuclear facilities, and front-line environments where precise radiation monitoring and safety are required.
• Mirion Medical group: Concentrated on medical uses of ionizing radiation. The group’s solutions are described as helping to enhance delivery and ensure safety in nuclear medicine, radiation therapy quality assurance, occupational dosimetry, and diagnostic imaging.

In addition, Mirion has described its operations more broadly in terms of Nuclear & Safety and Medical segments. The Medical segment is described as improving the quality and safety of cancer care delivery and supporting applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment is described as powering advancements in nuclear energy and critical radiation safety, measurement, and analysis applications across laboratories, research, and industrial markets such as defense.

Acquisition of Paragon Energy Solutions

Mirion has expanded its nuclear-focused capabilities through acquisitions. On September 24, 2025, the company entered into an Equity Purchase Agreement to acquire WCI-Gigawatt Intermediate Holdco, LLC, the indirect parent of Paragon Energy Solutions, LLC, for $585 million in an all-cash transaction, subject to customary adjustments and conditions, as disclosed in a Form 8-K. A subsequent Form 8-K dated December 1, 2025, states that Mirion completed this acquisition.

Company news releases describe Paragon as one of the leading providers of highly engineered solutions for the nuclear power industry, including large-scale nuclear power plants and small modular reactors (SMRs). Paragon’s offerings are described as an industry-leading portfolio of application-specific critical nuclear systems that support both the operating nuclear fleet and the next generation of SMR projects. Areas of expertise mentioned include commercial grade dedication and qualification of nuclear parts, testing and inspection, and value-add distribution via a proprietary platform. Mirion has stated that Paragon’s systems and solutions are present in 100% of nuclear reactors in North America and that Paragon will integrate into the Mirion Nuclear & Safety group.

Mirion’s press releases indicate that the Paragon acquisition is intended to broaden the company’s portfolio of offerings for nuclear power customers, including SMRs, and to enhance its presence in the U.S. nuclear power market. The company also notes that integrating Paragon’s engineering capabilities and complementary offerings with Mirion’s nuclear technology portfolio and global reach is expected to establish a more comprehensive set of solutions for the evolving nuclear power industry.

Capital markets activity and financing

Mirion is listed on the New York Stock Exchange under the ticker symbol MIR. The company has engaged in public equity and debt offerings as part of its financing strategy. In September 2025, Mirion announced and then priced an underwritten public offering of Class A common stock. A Form 8-K dated September 30, 2025, describes an underwriting agreement covering 19,906,322 shares of Class A common stock at a specified public offering price, with net proceeds intended to help fund the Paragon acquisition and pay the cost of capped call transactions related to a convertible notes offering, with any remainder for general corporate purposes.

On the same date, Mirion completed a private offering of Convertible Senior Notes due 2031, as detailed in the same Form 8-K. The notes are described as general unsecured obligations of the company, convertible into cash, shares of Class A common stock, or a combination, at Mirion’s election, subject to specified conditions and terms. The company has also disclosed subsequent credit agreement amendments and refinancing activities, including a new tranche of term loans maturing in 2032, as described in Form 8-K filings in November and December 2025.

Partnerships and global engagement

Mirion has described collaborations that align with its focus on radiation safety and measurement. In a September 2025 news release, the company announced a partnership agreement and practical arrangements with the International Atomic Energy Agency (IAEA) to cooperate in radiation detection and measurement. The agreement is described as supporting the IAEA’s Terrestrial Environmental Radiochemistry (TERC) Laboratory and related initiatives.

According to the company, this collaboration includes active participation in key projects at the TERC Laboratory, training and capacity building through educational materials and courses, assistance in measurement of samples and sharing of measurement data, and support of an annual intern through a Mirion scholarship. Mirion has also stated that it will aid the analytical capabilities of the TERC lab through an in-kind donation of instrumentation and software for training, testing, evaluation, and sample analysis.

Industry classification and role

Mirion operates within the electromedical and electrotherapeutic apparatus manufacturing industry and the broader manufacturing sector. Its focus on radiation safety, science, and medicine places it at the intersection of nuclear technology and healthcare. Company descriptions emphasize that Mirion’s technologies are used in nuclear energy, medical diagnostics and therapy, defense-related environments, and research laboratories, where precise radiation detection and monitoring are critical.

Across its disclosures, Mirion consistently highlights themes of safety, measurement accuracy, and support for both existing nuclear infrastructure and emerging technologies such as small modular reactors. In healthcare, the company emphasizes enhancing the quality and safety of cancer care and other radiation-based medical practices. These roles are reflected in its two main groups, Mirion Nuclear & Safety and Mirion Medical, and in its stated commitment to using knowledge of ionizing radiation to benefit the human condition.

FAQs about Mirion Technologies, Inc. (MIR)